We look at some of the key biotech developments, companies, and clinical data to watch at AHA Scientific Sessions 2026.

The companies Summit Therapeutics, Dren Bio, and Lycia Therapeutics bagged the biggest biotech funding rounds overall in October 2026.

ESMO 2026 was the hotspot for cancer research readouts, with encouraging trials across indications and therapeutic candidates ...

While Teva is initially known for its generics business, the company is shifting its strategy to build a more innovative ...

Look into the landscape around TROP2 ADCs as frontrunners aim to expand and the next wave aims to develop safer drugs.

In an interview with Labiotech, Jacobs discussed the decisions behind Novavax’s transformation, the economics of its new ...

Discover six companies advancing promising treatments for pulmonary hypertension beyond vasodilators, changing the standards of care.

Join leading experts to explore practical strategies for designing and delivering rare disease clinical trials in Europe.

The priciest merger and acquisition (M&A) last month was Shionogi’s $2 billion buyout of IntraBio, a Texas-based company focused on treating rare and neurodegenerative diseases. The American biotech ...

For much of the past decade, the advanced therapy industry has been focused on building the capabilities required to support growth. Manufacturing capacity needed to expand, clinical networks needed ...

For years, macrocyclic drugs have occupied a niche space in the pharmaceutical landscape, offering drugmakers a way to tackle biological targets that conventional small molecules struggle to reach.

GLP-1 is a hormone that is produced in the small intestine. The hormone binds to its receptor, which is expressed in various cells including in the pancreas, kidneys, heart, and skin. This hormone ...